StockData

Fennec Pharmaceuticals vs Pelthos Therapeutics

FENC and PTHS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FENC and PTHS compare

Fennec Pharmaceuticals is the larger company, worth 18 times as much as Pelthos Therapeutics ($476M against $26.2M).

Fennec Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −5.5% compared with −200% at Pelthos Therapeutics.

Fennec Pharmaceuticals scores higher on the StockData Score (7 against 2 for Pelthos Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFENCPTHS
Size and price
Market cap$476M$26.2M
Share price$13.58$6.84
Change, 1 year72.8%−79.6%
Change, 5 years40.9%–
Beta (5Y)1.890.97
Employees3592
StockData Score
Total score7 (better)2
Valuation score01 (better)
Growth score2 (better)0
Performance score3 (better)0
Health score2 (better)1
Dividend score00
Valuation
P/S8.0×0.6× (better)
P/B11.2×–
Fair value$7.22–
Margin of safety−88.0%–
Growth
Revenue growth (TTM)77.8%–
Revenue growth, 5Y average195%–
Profitability
Gross margin–78.6%
Operating margin−1.9% (better)−133%
Net margin−5.5% (better)−200%
Return on equity−18.6%–
Financial health
Interest coverage−1.2× (better)−7.8×
Current ratio5.85 (better)1.98
Altman Z-score6.06 (better)−1.84
Piotroski F-score15 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions46.5%35.6%
Insider net buying, 12 months−$9.9M$794K (better)

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.